Saturday 17 October 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 18.2% and free cash flow fell 116.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.98
0.70
−8.06%
Follow IMMX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (34.18%) | (74.46%) | (55.00%) | (182.55%) |
+8 more TTM periods Free account |
|
| (31.34%) | (60.47%) | (46.07%) | (104.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(17.60%) | (41.57%) | (31.44%) | (291.17%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.61) | (0.59) | (0.75) | (0.48) | |
Free Cash Flow |
(39.09) | (32.77) | (24.66) | (15.45) | |
Capital Expenditures |
(0.59) | (0.70) | (0.73) | (1.07) | |
| Other line items | |||||
Cash ROIC |
(8.48%) | (18.73%) | (12.70%) | (63.82%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.96 | 0.92 | 0.81 | 0.61 | |
Depreciation/Fixed assets |
0.21 | 0.18 | 0.14 | 0.13 | |
Capex/Depreciation |
(1.21) | (1.60) | (2.01) | (3.41) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.60) | (0.58) | (0.73) | (0.45) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates